BioequivalenceNCT06050343
Comparative Study of Rinsulin R (GEROPHARM) and Humulin Regular (Eli Lilly) Euglycemic Hyperinsulinemic Clamp Method
A study testing Humulin® Regular and Rinsulin® R in people with Bioequivalence and Therapeutic Equivalency, run by Geropharm at 1 site in Russia.
Trial summary
Pharmacokinetics and pharmacodynamics of Rinsulin® R, injection solution, 100 IU / ml (GEROPHARM LLC, Russia) and Humulin® Regular, injection solution, 100 IU / ml (Lilly France ", France) using the euglycemic hyperinsulinemic clamp method. Read more about this study
- Who is it for?
- Ages 18 to 50 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Bioequivalence, Therapeutic Equivalency
- What is being tested?
- Humulin® Regular and Rinsulin® R
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteRussia
- Study dates
- 19 Feb 2018to 4 May 2018
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Signed informed consent to participate in the study.
- Men of the Caucasian race with a verified diagnosis "healthy" according to the data of standard clinical, laboratory and instrumental examination methods.
- Age 18-50, inclusive.
- Body mass index 18.5 - 27 kg / m2.
- Volunteers who have sexual contact with fertile women should agree to use barrier methods of contraception while participating in the study (unless they have undergone surgical sterilization). Study Participants must also not become a sperm donor within the specified period.
- Consent to all restrictions imposed during the study.
Who cannot join
- Acute inflammatory diseases within 3 weeks from the moment of complete recovery to the stage of screening.
- Presence of episodes of hypoglycemia in the history of the volunteer
- Presence in the family history of the closest relatives cases of verified diagnosis of diabetes mellitus of any type.
- Deviations from the norm of basic vital indicators (heart rate, blood pressure, respiratory rate, body temperature) and ECG from normal values and laboratory values from reference values during screening.
- Fasting plasma glucose> 6.1 mmol / L at screening.
- HbA1C> 6% at the time of screening.
Show all 25Show fewer
- Oral glucose tolerance test - blood glucose level ≥7.8 mmol / L (2 hours after glucose loading) during screening.
- Hard-to-reach veins of the upper extremities, vein thrombosis, history of thrombophlebitis or family history of close relatives, "compromised" veins due to frequent preceding venipuncture.
- Taking medications, phytopreparations, biologically active additives within 14 days before screening.
- Significant blood loss 3 months before screening due to, for example, but not limited to the following points: a. donor blood donation; b. extended surgery or trauma leading to significant blood loss.
- Incomplete recovery from surgery or surgery scheduled while the volunteer is participating in the study.
- Mental, physical and other reasons interferes with adequately assessing behavior and correctly fulfill the conditions of the research protocol (incl. a history of mental illness).
- Presence or history (three years before the the study drug) of narcotic, drug and / or substance abuse.
- Positive test for the content of narcotic drugs in urine during the screening period.
- Anamnestic information about alcoholism or taking more than 10 units. alcohol per week (1 unit of alcohol is equivalent to 0.5 liters of beer, 200 ml of dry wine or 50 ml of spirits).
- Positive test for alcohol in breath during screening.
- Nicotine addiction (regular use of tobacco less than 6 months before screening).
- Any chronic diseases, incl. but not limited to positive test results for hepatitis C or hepatitis B, HIV, syphilis at the time of screening.
- Burdened allergological history.
- Presence of suspicion of an inflammatory disease of the urinary system based on the results of urinalysis during screening.
- Presence of oncological diseases within 5 years before the screening.
- History of organ transplantation (except of corneal transplant performed more than 3 months before the first injection of the study drug).
- Participation in a clinical trial of any drug or experimental medical device within 3 months prior to the first administration of the study drug.
- Any other condition that, in the reasonable opinion of the research physician, makes it difficult for the volunteer to participate in the study.
- History of hypersensitivity to heparin, insulin or any of the excipients of the investigational drugs.
Trial locations and contacts
1 site in 1 country.
Russia1 site
"National Medical Research Center of Endocrinology" of the Ministry of Health of the Russian Federation
Moscow, 117036
About this study
Official title: Comparative Study of the Pharmacokinetics and Pharmacodynamics of Rinsulin® R, Solution for Injection, 100 IU/ml (GEROPHARM LLC) and Humulin® Regular, Solution for Injection, 100 IU/ml (Eli Lilly) in Euglycemic Hyperinsulinemic Clamp Method
Pharmacokinetics and pharmacodynamics of Rinsulin® R, injection solution, 100 IU / ml (GEROPHARM LLC, Russia) and Humulin® Regular, injection solution, 100 IU / ml (Lilly France ", France) using the euglycemic hyperinsulinemic clamp method.
Read the detailed description
A double-blind, randomized, comparative, crossover study of the pharmacokinetics and pharmacodynamics of Rinsulin® R, solution for injection, 100 IU / ml (GEROPHARM LLC, Russia) and Humulin® Regular, solution for injection, 100 IU / ml (Lilly France, France) using euglycemic hyperinsulinemic clamp method on healthy volunteers
- Conditions
- Bioequivalence, Therapeutic Equivalency
- Being tested
- Humulin® Regular, Rinsulin® R
- Keywords
- human recombinant insulin, euglycemic hyperinsulinemic clamp
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Humulin® RegularDrug
Also called Reference drug
subcutaneous injection at a dose of 0.3 IU / kg
Rinsulin® RDrug
Also called Test Drug
subcutaneous injection at a dose of 0.3 IU / kg
| Study group | Role | What they receive |
|---|---|---|
| Rinsulin® R | Experimental | Single subcutaneous administration of Insulin at a dose 0.3 IU / kg Receives: Drug: Humulin® Regular; Drug: Rinsulin® R |
| Humulin® Regular | Active comparator | Single subcutaneous administration of Insulin at a dose 0.3 IU / kg Receives: Drug: Humulin® Regular; Drug: Rinsulin® R |
What is being measured
The primary outcome is the main question the study is designed to answer.
Смах
Drug Observed Maximum Plasma Concentration
Measured: -60 minutes, -30 minutes, 0, every 15 minutes till 4 hours and then every 30 minutes till 10 hours
AUC 0-10
Total area under the curve "drug concentration - time" in the time interval from 0 to 10 h
Measured: -60 minutes, -30 minutes, 0, every 15 minutes till 4 hours and then every 30 minutes till 10 hours
AUC GIR 0-12
Total area under the curve "glucose infusion rate - time" in the time interval from 0 to 12 h
Measured: - 120 minutes, -90 minutes, -60 minutes, -30 minutes, 0, every 5 minutes till 8 hours, then every 10 minutes till 10 hours and then every 30 minutes till 12 hours
GIRmax
Time to reach maximum glucose infusion rate
Measured: -120 minutes, -90 minutes, -60 minutes, -30 minutes, 0, every 5 minutes till 8 hours, then every 10 minutes till 10 hours and then every 30 minutes till 12 hours
Secondary outcomes (10)
tGIRmax
Time to reach maximum glucose infusion rate
Measured: -120 minutes, -90 minutes, -60 minutes, -30 minutes, 0, every 5 minutes till 8 hours, then every 10 minutes till 10 hours and then every 30 minutes till 12 hours
AUC 0-2
Total area under the curve "drug concentration - time" in the time interval from 0 to 2 h
Measured: -60 minutes, -30 minutes, 0, every 15 minutes till 4 hours and then every 30 minutes till 10 hours
AUC 0-4
Total area under the curve "drug concentration - time" in the time interval from 0 to 4 h
Measured: -60 minutes, -30 minutes, 0, every 15 minutes till 4 hours and then every 30 minutes till 10 hours
AUC 0-6
Total area under the curve "drug concentration - time" in the time interval from 0 to 6 h
Measured: -60 minutes, -30 minutes, 0, every 15 minutes till 4 hours and then every 30 minutes till 10 hours
Tmax
Time to reach test drug Maximum Plasma Concentration
Measured: -60 minutes, -30 minutes, 0, every 15 minutes till 4 hours and then every 30 minutes till 10 hours
T1/2
Half-life of a test drug
Measured: -60 minutes, -30 minutes, 0, every 15 minutes till 4 hours and then every 30 minutes till 10 hours
tGIRlag
Time between the drug administration and the onset of action
Measured: -120 minutes, -90 minutes, -60 minutes, -30 minutes, 0, every 5 minutes till 8 hours, then every 10 minutes till 10 hours and then every 30 minutes till 12 hours
AUC GIR 0-2
Total area under the curve "glucose infusion rate - time" in the time interval from 0 to 2 h
Measured: -120 minutes, -90 minutes, -60 minutes, -30 minutes, 0, every 5 minutes till 8 hours, then every 10 minutes till 10 hours and then every 30 minutes till 12 hours
AUC GIR 0-4
Total area under the curve "glucose infusion rate - time" in the time interval from 0 to 4 h
Measured: - 120 minutes, -90 minutes, -60 minutes, -30 minutes, 0, every 5 minutes till 8 hours, then every 10 minutes till 10 hours and then every 30 minutes till 12 hours
AUC GIR 0-6
Total area under the curve "glucose infusion rate - time" in the time interval from 0 to 6 h
Measured: -120 minutes, -90 minutes, -60 minutes, -30 minutes, 0, every 5 minutes till 8 hours, then every 10 minutes till 10 hours and then every 30 minutes till 12 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Sep 2023
- Study start19 Feb 2018
- Primary completion4 May 2018
- Study completion4 May 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for BioequivalenceStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Crossover Assignment two-way crossover
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- Geropharm
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06050343
- Sponsor's protocol ID
- RINCL-R
- Status last verified
- Sep 2023
- First submitted
- 3 Aug 2020
- Last updated
- 22 Sep 2023
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Sep 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparative Study of the Pharmacokinetics and Pharmacodynamics of Rinsulin® R, Solution for Injection, 100 IU/ml (GEROPHARM LLC) and Humulin® Regular, Solution for Injection, 100 IU/ml (Eli Lilly) in Euglycemic Hyperinsulinemic Clamp Method
- ClinicalTrials.gov ID
- NCT06050343
- Acronym / sponsor ID
- RINCL-R
- Conditions
- Bioequivalence, Therapeutic Equivalency
- Keywords
- human recombinant insulin, euglycemic hyperinsulinemic clamp
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- GeropharmIndustry (pharma, biotech, devices)
- Study start
- 19 Feb 2018 (actual)
- Primary completion
- 4 May 2018 (actual)
- Study completion
- 4 May 2018 (actual)
- First posted
- 22 Sep 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Pharmacokinetics and pharmacodynamics of Rinsulin® R, injection solution, 100 IU / ml (GEROPHARM LLC, Russia) and Humulin® Regular, injection solution, 100 IU / ml (Lilly France ", France) using the euglycemic hyperinsulinemic clamp method.
Detailed description
A double-blind, randomized, comparative, crossover study of the pharmacokinetics and pharmacodynamics of Rinsulin® R, solution for injection, 100 IU / ml (GEROPHARM LLC, Russia) and Humulin® Regular, solution for injection, 100 IU / ml (Lilly France, France) using euglycemic hyperinsulinemic clamp method on healthy volunteers
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
- Model description
- Crossover Assignment two-way crossover
| Arm | Type | Receives |
|---|---|---|
| Rinsulin® R | Experimental | Drug: Humulin® Regular, Drug: Rinsulin® RSingle subcutaneous administration of Insulin at a dose 0.3 IU / kg |
| Humulin® Regular | Active comparator | Drug: Humulin® Regular, Drug: Rinsulin® RSingle subcutaneous administration of Insulin at a dose 0.3 IU / kg |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- Signed informed consent to participate in the study.
- Men of the Caucasian race with a verified diagnosis "healthy" according to the data of standard clinical, laboratory and instrumental examination methods.
- Age 18-50, inclusive.
- Body mass index 18.5 - 27 kg / m2.
- Volunteers who have sexual contact with fertile women should agree to use barrier methods of contraception while participating in the study (unless they have undergone surgical sterilization). Study Participants must also not become a sperm donor within the specified period.
Key exclusion criteria (25 listed)
- Acute inflammatory diseases within 3 weeks from the moment of complete recovery to the stage of screening.
- Presence of episodes of hypoglycemia in the history of the volunteer
- Presence in the family history of the closest relatives cases of verified diagnosis of diabetes mellitus of any type.
- Deviations from the norm of basic vital indicators (heart rate, blood pressure, respiratory rate, body temperature) and ECG from normal values and laboratory values from reference values during screening.
- Fasting plasma glucose> 6.1 mmol / L at screening.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Humulin® RegularAlso: Reference drugsubcutaneous injection at a dose of 0.3 IU / kg | Drug | Humulin® Regular, Rinsulin® R |
| Rinsulin® RAlso: Test Drugsubcutaneous injection at a dose of 0.3 IU / kg | Drug | Humulin® Regular, Rinsulin® R |
Primary outcome
Смах
Time frame: -60 minutes, -30 minutes, 0, every 15 minutes till 4 hours and then every 30 minutes till 10 hours
Drug Observed Maximum Plasma Concentration
AUC 0-10
Time frame: -60 minutes, -30 minutes, 0, every 15 minutes till 4 hours and then every 30 minutes till 10 hours
Total area under the curve "drug concentration - time" in the time interval from 0 to 10 h
AUC GIR 0-12
Time frame: - 120 minutes, -90 minutes, -60 minutes, -30 minutes, 0, every 5 minutes till 8 hours, then every 10 minutes till 10 hours and then every 30 minutes till 12 hours
Total area under the curve "glucose infusion rate - time" in the time interval from 0 to 12 h
GIRmax
Time frame: -120 minutes, -90 minutes, -60 minutes, -30 minutes, 0, every 5 minutes till 8 hours, then every 10 minutes till 10 hours and then every 30 minutes till 12 hours
Time to reach maximum glucose infusion rate
10 secondary outcomes
tGIRmax
Time frame: -120 minutes, -90 minutes, -60 minutes, -30 minutes, 0, every 5 minutes till 8 hours, then every 10 minutes till 10 hours and then every 30 minutes till 12 hours
AUC 0-2
Time frame: -60 minutes, -30 minutes, 0, every 15 minutes till 4 hours and then every 30 minutes till 10 hours
AUC 0-4
Time frame: -60 minutes, -30 minutes, 0, every 15 minutes till 4 hours and then every 30 minutes till 10 hours
AUC 0-6
Time frame: -60 minutes, -30 minutes, 0, every 15 minutes till 4 hours and then every 30 minutes till 10 hours
Tmax
Time frame: -60 minutes, -30 minutes, 0, every 15 minutes till 4 hours and then every 30 minutes till 10 hours
T1/2
Time frame: -60 minutes, -30 minutes, 0, every 15 minutes till 4 hours and then every 30 minutes till 10 hours
tGIRlag
Time frame: -120 minutes, -90 minutes, -60 minutes, -30 minutes, 0, every 5 minutes till 8 hours, then every 10 minutes till 10 hours and then every 30 minutes till 12 hours
AUC GIR 0-2
Time frame: -120 minutes, -90 minutes, -60 minutes, -30 minutes, 0, every 5 minutes till 8 hours, then every 10 minutes till 10 hours and then every 30 minutes till 12 hours
AUC GIR 0-4
Time frame: - 120 minutes, -90 minutes, -60 minutes, -30 minutes, 0, every 5 minutes till 8 hours, then every 10 minutes till 10 hours and then every 30 minutes till 12 hours
AUC GIR 0-6
Time frame: -120 minutes, -90 minutes, -60 minutes, -30 minutes, 0, every 5 minutes till 8 hours, then every 10 minutes till 10 hours and then every 30 minutes till 12 hours
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Sep 2023.
- Individual participant dataSharing planned: No
Related trials for Bioequivalence
Not yet recruitingPhase 1
A Study of Imlunestrant (LY3484356) in Healthy Female Participants
Healthy
RecruitingPhase 1
A Randomized, Double-Blind, Positive-Controlled, Parallel Pharmacokinetic Phase I Clinical Study of Cetuximab Injection Versus Erbitux in Healthy Male Subjects
Cetuximab, Bioequivalence
RecruitingPhase 1
Bioequivalence Study Between YHP2508B and YHR2602 in Healthy Subjects
Healthy Subjects (HS)
Active, not recruitingPhase 1
A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer
Prostatic Neoplasms
RecruitingPhase 1
Bioequivalence Study Between YHP2508A and YHR2601 in Healthy Subjects
Healthy Subjects (HS)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Humulin® Regular and Rinsulin® R in people with Bioequivalence and Therapeutic Equivalency, run by Geropharm at 1 site in Russia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 25 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Sep 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Russia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Смах (time frame: -60 minutes, -30 minutes, 0, every 15 minutes till 4 hours and then every 30 minutes till 10 hours). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Sep 2023.